External validation of the Briganti 2019 nomogram to identify candidates for extended pelvic lymph node dissection among patients with high-risk clinically localized prostate cancer

Table 1 Variables included in nomograms predicting lymph node invasion at radical prostatectomy in patients with prostate cancer

Nomogram	Covariates
Briganti 2019^† [7]	PSA at diagnosis
	Clinical stage on multiparametric MRI
	Grade group on MRI-targeted biopsy
	Maximum diameter of the index lesion on multiparametric MRI
	Percentage of positive cores with clinically significant cancer on systematic biopsy
Briganti 2017^‡ [16]	Biopsy Gleason grade group
	Clinical stage
	Preoperative PSA
	Percentage of positive cores with the highest-grade disease
	Percentage of positive cores with the lower-grade disease
Briganti 2012^§ [17]	PSA at diagnosis
	Clinical stage
	Primary Gleason grade
	Secondary Gleason grade
	Percentage of positive cores
MSKCC^¶ [18]	Preoperative PSA
	Primary biopsy Gleason grade
	Secondary biopsy Gleason grade
	Clinical stage
	Number of negative cores
	Number of positive cores
Partin 2017^†† [19]	Preoperative PSA (0–4, 4.1–6, 6.1–10 and greater than 10 ng/ml)
	Gleason score (5–6, 3 + 4, 4 + 3/8, and 9–10)
	Clinical stage (T1c, T2a and T2b/T2c)
Japan PC table^‡‡ [20]	Preoperative PSA (0–4, 4.1–6, 6.1–8, 8.1–10, and greater than 10 ng/ml)
	Gleason score (6, 3 + 4, 4 + 3, and 8–10)
	Clinical stage (T1c, T2a, T2b, and T2c)